Terra Nova Asset Management LLC Takes Position in Genmab A/S Sponsored ADR $GMAB

Terra Nova Asset Management LLC purchased a new stake in shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB) during the 4th quarter, Holdings Channel reports. The fund purchased 60,600 shares of the company’s stock, valued at approximately $1,866,000.

Other institutional investors also recently bought and sold shares of the company. DAVENPORT & Co LLC boosted its stake in Genmab A/S by 33.6% during the fourth quarter. DAVENPORT & Co LLC now owns 44,761 shares of the company’s stock worth $1,379,000 after buying an additional 11,265 shares during the period. Wealth Enhancement Advisory Services LLC lifted its stake in Genmab A/S by 10.0% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 14,818 shares of the company’s stock worth $490,000 after purchasing an additional 1,350 shares during the last quarter. Park Avenue Securities LLC lifted its stake in Genmab A/S by 6.3% in the fourth quarter. Park Avenue Securities LLC now owns 17,870 shares of the company’s stock worth $550,000 after purchasing an additional 1,066 shares during the last quarter. GAMMA Investing LLC boosted its position in shares of Genmab A/S by 59.5% during the fourth quarter. GAMMA Investing LLC now owns 4,755 shares of the company’s stock valued at $146,000 after buying an additional 1,773 shares during the period. Finally, Caitong International Asset Management Co. Ltd grew its stake in shares of Genmab A/S by 23.5% during the third quarter. Caitong International Asset Management Co. Ltd now owns 7,172 shares of the company’s stock valued at $220,000 after buying an additional 1,363 shares during the last quarter. 7.07% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the company. Jefferies Financial Group started coverage on Genmab A/S in a report on Tuesday, February 17th. They issued a “buy” rating and a $41.50 price target on the stock. Truist Financial raised Genmab A/S to a “strong-buy” rating in a research report on Wednesday. HC Wainwright increased their target price on Genmab A/S from $39.00 to $40.00 and gave the stock a “buy” rating in a research note on Wednesday, February 18th. Morgan Stanley started coverage on Genmab A/S in a research report on Monday, February 16th. They set an “equal weight” rating and a $34.00 target price for the company. Finally, Guggenheim lowered their target price on shares of Genmab A/S from $45.00 to $40.00 and set a “buy” rating for the company in a research note on Monday, February 23rd. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Genmab A/S presently has a consensus rating of “Moderate Buy” and an average price target of $39.36.

Genmab A/S Stock Performance

Genmab A/S stock opened at $25.82 on Friday. The company has a debt-to-equity ratio of 0.86, a quick ratio of 2.01 and a current ratio of 2.02. The company has a market capitalization of $16.59 billion, a PE ratio of 16.66, a P/E/G ratio of 1.06 and a beta of 0.94. The company has a 50 day moving average price of $29.40 and a 200-day moving average price of $30.47. Genmab A/S Sponsored ADR has a fifty-two week low of $17.24 and a fifty-two week high of $35.43.

Genmab A/S (NASDAQ:GMAB) last announced its quarterly earnings data on Tuesday, February 17th. The company reported $0.05 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.46 by ($0.41). The firm had revenue of $1.06 billion during the quarter, compared to the consensus estimate of $1.06 billion. Genmab A/S had a return on equity of 17.35% and a net margin of 25.89%. As a group, equities analysts forecast that Genmab A/S Sponsored ADR will post 1.45 earnings per share for the current year.

About Genmab A/S

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.